Other Information
−Removed: Subsequent to March 31, 2026, on May 13, 2026, the Company and a majority-in-interest of the holders of the 2024 Convertible Notes entered into a waiver agreement, pursuant to which they agreed that the holders would not declare that an event of default has occurred due to the Company's failure to obtain a positive Medicare decision with respect to its EsoGuard product by May 22, 2026.
−Removed: Such waiver covers the period through August 22, 2026.
−Removed: During the fiscal quarter ended March 31, 2026 , none of our directors or officers (as defined in Rule 16a - 1 under the Exchange Act) adopted or terminated a “Rule 10b5 - 1 trading arrangement” or “non-Rule 10b5 - 1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).
+Added: During the fiscal quarter ended June 30, 2026 , none of our directors or officers (as defined in Rule 16a - 1 under the Exchange Act) adopted or terminated a “Rule 10b5 - 1 trading arrangement” or “non-Rule 10b5 - 1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).
The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth in the “ Exhibit Index ” below.
1 unchanged sentence
Incorporation by Reference
+Added: Certificate of Amendment to Certificate of Incorporation, dated June 24, 2026.
Underwriting Agreement (April RDO)
14 unchanged sentences
Lucid Diagnostics Inc.
+Added: August 12, 2026
/s/ Dennis M McGrath
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.